Peter Lin1,2,3, Myo Min4,5,6, Mark Lee4,5, Lois Holloway4,7,5,6, Dion Forstner4,5,6, Victoria Bray5, Allan Fowler5. 1. Department of Nuclear Medicine and PET, Liverpool Hospital, Locked Bag 7103, Liverpool BC, NSW, Australia. peter.lin@sswahs.nsw.gov.au. 2. South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia. peter.lin@sswahs.nsw.gov.au. 3. Western Sydney University, Sydney, NSW, Australia. peter.lin@sswahs.nsw.gov.au. 4. South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia. 5. Cancer Therapy Centre, Liverpool Hospital, Liverpool, NSW, Australia. 6. Ingham Institute of Applied Medical Research, Liverpool, NSW, Australia. 7. Western Sydney University, Sydney, NSW, Australia.
Abstract
PURPOSE: To evaluate the prognostic utility of nodal metabolic parameters derived from FDG PET/CT performed before radiotherapy (prePET) and during the third week of radiotherapy (iPET) in patients with mucosal primary head and neck squamous cell carcinoma (MPHNSCC). METHODS: This analysis included 75 patients with newly diagnosed locally advanced node-positive MPHNSCC treated with radical radiotherapy and concurrent systemic therapy who underwent prePET and iPET: N1 11 patients, N2a 38, N2b 12, N2c 9, N3 5. The median follow-up was 28 months (9 - 70 months). The maximum and mean standardized uptake values (SUVmax and SUVmean), metabolic tumour volume (MTV) and total lesional glycolysis (TLG) of the index lymph node (node with the highest TLG) and the combined total lymph nodes, and their percentage reductions on iPET were determined, and the results were correlated with 3-year Kaplan-Meier locoregional, regional and distant metastatic failure-free survival (FFS), disease-free survival (DFS) and overall survival (OS). Optimal cut-off values were derived from receiver operating characteristic curves. Cox regression univariate and multivariate analyses with clinical covariates were performed. RESULTS: Based on assessment of residual nodal metabolic burden during treatment, the iPET index node SUVmean (optimal cut-off value 2.95 g/ml) and the total node SUVmean (optimal cut-off value 3.25) were the best independent predictors of outcome in the multivariate analysis: index node SUVmean for DFS and OS p = 0.033 and 0.003, respectively, and the total node SUVmean for locoregional FFS, DFS and OS p = 0.028, 0.025 and 0.014, respectively. Based on the assessment of response rates during treatment, a reduction of more than 50 % in the total node TLG was the best biomarker for locoregional and regional FFS, DFS and OS in the multivariate analysis (p = 0.001, 0.016, 0.001 and 0.004, respectively), and reduction in the total node MTV for locoregional FFS, DFS and OS (p = 0.026, 0.003 and 0.014, respectively). There were no significant correlations between oncological outcomes and prePET nodal parameters. CONCLUSION: We demonstrated that the index node and total node SUVmean on iPET and a reduction of more than 50 % in MTV and TLG are useful imaging biomarkers, and can potentially identify those patients with MPHNSCC who have a high risk of locoregional metastatic failure and death.
PURPOSE: To evaluate the prognostic utility of nodal metabolic parameters derived from FDG PET/CT performed before radiotherapy (prePET) and during the third week of radiotherapy (iPET) in patients with mucosal primary head and neck squamous cell carcinoma (MPHNSCC). METHODS: This analysis included 75 patients with newly diagnosed locally advanced node-positive MPHNSCC treated with radical radiotherapy and concurrent systemic therapy who underwent prePET and iPET: N1 11 patients, N2a 38, N2b 12, N2c 9, N3 5. The median follow-up was 28 months (9 - 70 months). The maximum and mean standardized uptake values (SUVmax and SUVmean), metabolic tumour volume (MTV) and total lesional glycolysis (TLG) of the index lymph node (node with the highest TLG) and the combined total lymph nodes, and their percentage reductions on iPET were determined, and the results were correlated with 3-year Kaplan-Meier locoregional, regional and distant metastatic failure-free survival (FFS), disease-free survival (DFS) and overall survival (OS). Optimal cut-off values were derived from receiver operating characteristic curves. Cox regression univariate and multivariate analyses with clinical covariates were performed. RESULTS: Based on assessment of residual nodal metabolic burden during treatment, the iPET index node SUVmean (optimal cut-off value 2.95 g/ml) and the total node SUVmean (optimal cut-off value 3.25) were the best independent predictors of outcome in the multivariate analysis: index node SUVmean for DFS and OS p = 0.033 and 0.003, respectively, and the total node SUVmean for locoregional FFS, DFS and OS p = 0.028, 0.025 and 0.014, respectively. Based on the assessment of response rates during treatment, a reduction of more than 50 % in the total node TLG was the best biomarker for locoregional and regional FFS, DFS and OS in the multivariate analysis (p = 0.001, 0.016, 0.001 and 0.004, respectively), and reduction in the total node MTV for locoregional FFS, DFS and OS (p = 0.026, 0.003 and 0.014, respectively). There were no significant correlations between oncological outcomes and prePET nodal parameters. CONCLUSION: We demonstrated that the index node and total node SUVmean on iPET and a reduction of more than 50 % in MTV and TLG are useful imaging biomarkers, and can potentially identify those patients with MPHNSCC who have a high risk of locoregional metastatic failure and death.
Entities:
Keywords:
FDG PET/CT; Imaging biomarkers; Mucosal primary head and neck squamous cell carcinoma; Positron emission tomography; Radiotherapy
Authors: Sandro V Porceddu; David I Pryor; Elizabeth Burmeister; Bryan H Burmeister; Michael G Poulsen; Matthew C Foote; Benedict Panizza; Scott Coman; David McFarlane; William Coman Journal: Head Neck Date: 2011-01-14 Impact factor: 3.147
Authors: Charlotte L Brouwer; Roel J H M Steenbakkers; Johannes A Langendijk; Nanna M Sijtsema Journal: Radiother Oncol Date: 2015-06-17 Impact factor: 6.280
Authors: M Min; P Lin; M Lee; I Ho Shon; M Lin; D Forstner; M T Tieu; A Chicco; V Bray; A Fowler Journal: Clin Oncol (R Coll Radiol) Date: 2016-01-11 Impact factor: 4.126
Authors: Trang H La; Edith J Filion; Brit B Turnbull; Jackie N Chu; Percy Lee; Khoa Nguyen; Peter Maxim; Andy Quon; Edward E Graves; Billy W Loo; Quynh-Thu Le Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-14 Impact factor: 7.038
Authors: Myo Min; Mark T Lee; Peter Lin; Lois Holloway; Dj Wijesekera; Dinesh Gooneratne; Robba Rai; Wei Xuan; Allan Fowler; Dion Forstner; Gary Liney Journal: Br J Radiol Date: 2015-12-09 Impact factor: 3.039
Authors: Angela van Baardwijk; Christophe Dooms; Robert Jan van Suylen; Erik Verbeken; Monique Hochstenbag; Cary Dehing-Oberije; Dennis Rupa; Silvia Pastorekova; Sigrid Stroobants; Ulrich Buell; Philippe Lambin; Johan Vansteenkiste; Dirk De Ruysscher Journal: Eur J Cancer Date: 2007-05-23 Impact factor: 9.162
Authors: K S Clifford Chao; Gokhan Ozyigit; Binh N Tran; Mustafa Cengiz; James F Dempsey; Daniel A Low Journal: Int J Radiat Oncol Biol Phys Date: 2003-02-01 Impact factor: 7.038
Authors: Joël Castelli; A Depeursinge; A Devillers; B Campillo-Gimenez; Y Dicente; J O Prior; E Chajon; F Jegoux; C Sire; O Acosta; E Gherga; X Sun; B De Bari; J Bourhis; R de Crevoisier Journal: Eur J Nucl Med Mol Imaging Date: 2018-08-21 Impact factor: 9.236
Authors: Pierluigi Bonomo; A Merlotti; E Olmetto; A Bianchi; I Desideri; A Bacigalupo; P Franco; C Franzese; E Orlandi; L Livi; S Caini Journal: Eur J Nucl Med Mol Imaging Date: 2018-06-09 Impact factor: 9.236
Authors: Jefferson Rijo-Cedeño; Jorge Mucientes; Ithzel María Villarreal; Ana Royuela; Patricia García Vicente; José Ramón García-Berrocal Journal: Eur Arch Otorhinolaryngol Date: 2022-05-02 Impact factor: 3.236